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ABSTRACT 
Opioid use in the United States is skyrocketing. Overdose deaths have increased 433% in 
the last decade and will continue climbing. In addition to the mortality caused by illicit 
opioid misuse, morbidity rates have also risen. People Who Inject Drugs (PWID) 
demonstrate higher rates of Human Immunodeficiency Virus (HIV), Hepatitis C Virus 
(HCV), Endocarditis, Persistent Abscesses, Staphylococcus Aureus (S. aureus, Staph) 
and other skin infections. This thesis serves as (1) a systematic review of the differences 
in health conditions experienced by PWID and (2) an examination of the trends in skin 
and soft tissue infection from a small sample in Phoenix, Arizona. The author argues that 
PWID suffer from an increased rate of comorbid conditions associated with substance 
use. Targeted social work interventions could be useful in reducing the rates of disease 
and their impact on the individual and community. 
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Background 
Opioid Use Increasing 
According to the United States Centers for Disease Control and Prevention 
(CDC), the United States is facing a drastic increase in the number of prescriptions 
written for opiate pain medication (OPM), nearly quadrupling from 1999 to 2014 
(Centers for Disease Control and Prevention (CDC), 2017). From 2005 until 2011 the 
number of emergency room visits due to opioid pain medicine rose 117% and accounted 
for 29% of all hospital admissions (Crane, 2013). However, measures to decrease these 
deaths have varied from state to state.  In Arizona, few practical steps are being taken to 
address the real issue, and in fact, according to a Pew Research Study, “only 16% of 
Americans believed that the United States was making progress in reducing prescription-
drug abuse” (Doherty, 2013). Prescription opioid misuse is a serious problem in the 
United States  (Dart, Surratt, Cicero, Parrino, Severtson, Bucher-Bartelson, & Green, 
2015; Han, Compton, Blanco, Crane, Lee, & Jones, 2017). 
 
Overdose Deaths Increasing 
  According to the CDC, between 1999 and 2016 there have been 351,630 opioid 
related deaths, increasing at a rate of 455%  (Tinker, 2019).  Nearly three million 
Americans have an opioid use disorder (OUD), 2 million of them being prescription 
opioids and 600,000 having an OUD involving heroin; every day nearly 90 Americans 
die from overdose (Jette, 2018). The increase in the number of overdoses due to OUD has 
reached epidemic proportions, with no community safe from its effects.  Unless steps are 
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taken to prevent overdose deaths, the numbers will continue to rise, and the cost on 
communities, families, and country will be ever greater. 
 
Acute Injection Related Injuries  
Complications from ODU may include overdose, and non-fatal overdose. 
However, overdose is not the only consequence of injection drug use (IDU).  Other 
illnesses and injuries can present due to IDU, including, Hepatitis C (HCV), Human 
Immunodeficiency Virus (HIV), and Acute Injection Related Injuries (AIRI) or Injection 
Related Infections or Disease (IRID) including soft tissue damage, abscesses, bone and 
joint infections, infective endocarditis and sepsis. In fact, from 2002 to 2012, inpatient 
hospitalizations increased at quadruple their normal rate for complex infections due to 
IDU (Goldstein, Wurcel, Merchant, Clark, & Stone, 2015; Ronan & Herzig, 2016). While 
death is the worst possible outcome for an individual, soft tissue damage and chronic 
illness are also significant impacts on the quality of life, health, and future outcome for 
individuals suffering from any substance use disorder (SUD). Reducing the frequency, 
intensity, and length of these injuries and illnesses would potentially provide for a better 
long-term health outcome and allow the individual to survive through their SUD with 
more of their health intact. Should the individual choose recovery, they would be in better 
physical health overall and therefore stand a better chance of being successful in their 
recovery to lead a longer and more productive life.  
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Literature Review 
The existing literature on opioid health effects, skin infections, blood infections, 
and related harms was examined in an attempt to better articulate the knowledgebase. The 
method for identifying studies for inclusion in this systematic literature review was based 
on a database search utilizing Google Scholar and the electronic library at Arizona State 
University. The terms utilized for inclusion in this study were: Opioid, Health, Risks, 
Heroin, Inject Drugs, Infection, and Endocarditis. The results of this search yielded 
numerous studies.  A large number of the studies came from outside of the United States, 
with Australia being a very common location for the research. There is a clear need for 
more research in the United States.  
 
Secondary Data Analysis 
A convenience sample of 82 persons in Phoenix, Arizona consisted of those 
utilizing one of two different syringe exchange sites located locally. When the individuals 
were finished gathering their supplies, they were asked if they would like to participate in 
a survey to gather information on persons who inject drugs (PWID) in Phoenix. The 
larger purpose of the study was to establish a baseline for the needs and wants of the 
community of PWID and to identify target areas of interactions with first responders in 
order to formulate a brief intervention. However, included in the survey materials were 
questions specific to the goal of this study which was identifying specific health impacts 
from injection drug use (IDU). The results of those survey responses are what provide the 
basis of this secondary data analysis. The purpose of this secondary data analysis was to 
gain a general understanding of the health conditions of PWID that relate to their skin 
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and soft tissue health. PWID are at a higher rate of skin infections, specifically those 
attributed to Staphylococcus aureus (Dahlman, Jalalvand, Blomé, Håkansson, Janson, 
Quick, & Nilsson, 2017). So, while researchers are generally familiar with the higher 
disease burden placed on PWID through their IDU on a broad scale, the research has not 
been conducted locally to determine if the same results are shared by PWID in Phoenix, 
Arizona.  
 
Purpose Statement 
The purpose of this study was to compare the known existing research on Acute 
Injection Related Injuries (AIRI) from studied populations, to a small sample of 
individuals in Phoenix, Arizona to establish whether the prevalence rates examined in 
existing research matches with the results shown locally.  
 
Study One – Comprehensive Literature Review 
Background 
Taking advantage of the research and data that have been gathered by studies, in 
different locales, can provide the insight and depth of knowledge necessary to formulate 
the proper research questions. The inquiry is related to the prevalence of skin and soft 
tissue infections in PWID. While there was a large amount of literature on the health 
impacts of substance abuse and IDU in a broad sense, focusing on such a narrow area of 
the literature revealed a substantial lack of research.   
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Methods 
The method for identifying studies for inclusion in this systematic literature 
review was based on Google Scholar and the electronic library at Arizona State 
University. The terms utilized for inclusion in this study were: Opioid, Health, Risks, 
Heroin, Inject Drugs, Infection, and Endocarditis. The results of this search yielded 
numerous studies.  Those studies considered for inclusion were only those published in 
peer-reviewed English language journals from 2008 until the present. The search yielded 
45 potential studies for inclusion in this literature review; of those, eight were removed 
for dealing primarily with patient care in the hospital setting, and not with harm reduction 
or AIRI prevalence; 10 were removed for dealing with population modeling and 
substance use trends; and four were removed for only dealing with treatment related 
issues. The remaining 23 studies had to meet specific inclusion criteria: (a) be conducted 
no earlier than 2008, in order to remain relevant to the current body of research on 
substance use, (b) deal exclusively with Injection Related Infection and Disease (IRID), 
Acute Infection Related Injury (AIRI), HIV, HCV, or Infective Endocarditis (IE), (c) be 
either primary research or a systematic review of primary research directly involving 
persons who inject drugs (PWID), and (d) be published in high quality journals as 
determined by the Journal Citation Report (JCR).  
 
Results 
Substance misuse is positively correlated with negative general physical and 
mental health overall, with PWID showing the strongest correlation (Lake & Kennedy, 
2016). Of particular note in this review are the studies of physical health effects of 
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injecting drugs, specifically HIV, HCV, infective endocarditis, and other AIRI. Harm 
reduction measures, such as: safer injection techniques, proper skin hygiene, and wound 
care are promoted in various countries around the world and are beneficial to the 
individual and the community. Harm reduction measures can lower the overall burden of 
morbidity and mortality on the IDU community, as well as the community at large.  
 
Harm Reduction Methods 
There are various harm reduction methodologies that reduce the burden of 
substance use on the user’s body, in order to prevent increased harm and improve quality 
of life. Prior to those harm reduction measures (in which participants are rarely, if ever 
taught proper safer injection techniques or wound care), 16% of individuals reported not 
cleaning their hands, applying a tourniquet correctly (38%), not applying pressure long 
enough (33%) and frequently missing a vein (56%) (Ivan, Rodgers, Maher, & Van Beek, 
2016). Safer injection technique education can improve outcomes; Sweden, which has a 
number of harm reduction programs for PWID, conducted a study with the Karolinska 
University Hospital during January 2004 to December 2013 and showed an incidence rate 
of staphylococcus aureus in IDUs of 249 vs 0.79 for the general population in 100,000 
person years (Asgeirsson, Thalme, & Weiland, 2016). However, by utilizing multiple 
harm reduction programs, actual rates of infection have been shown to decrease; utilizing 
interventions that combined substance-use treatment with support for SIFs was shown to 
reduce HCV seroconversion by 75% (Hagan, Pouget, & Des Jarlais, 2011). Overall, by 
utilizing harm reduction methods, the burden of death and disease was reduced in 
communities.  In fact, communities that utilized a broader range of harm reduction 
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measures showed the most positive health benefits (Stancliff, Phillips, Maghsoudi, & 
Joseph, 2015).  
 
Increased Burden of Disease 
The greatest potential impact of IDU was demonstrated in the increased burden of 
chronic disease. One study showed that 11% of PWID tested positive for HIV (Spiller, 
Broz, Wejnert, Nerlander, Paz-Bailey, Centers for Disease Control and Prevention 
(CDC), & National HIV Behavioral Surveillance System Study Group, 2015); however, 
when taught proper harm reduction methods for injecting substances, incidence rates for 
HIV fell overall (Aspinall, Nambiar, Goldberg, Hickman, Weir, Van Velzen, Palmateer, 
Doyle, Hellard, & Hutchinson, 2014). Similar trends were found with regards to HCV.  
When data from the National Notifiable Disease Surveillance System (NNDSS) was 
studied, researchers found that PWID are at a 4-fold increase for acquiring HCV (Zibbell, 
Asher, Patel, Kupronis, Iqbal, Ward, & Holtzman, 2018). Additionally, in a global 
systemic review of IDUs in nearly 80 countries, 60-80% of IDUs tested positive for anti-
HCV (Nelson, Mathers, Cowie, Hagan, Des Jarlais, Horyniak, & Degenhardt, 2011). The 
two studies conducted concerning infective endocarditis showed that IDU increased an 
individual’s risk by 14.3% specifically for the 15 – 34 year-old age group (Wurcel, 
Anderson, Chui, Skinner, Knox, Snydman, & Stopka, 2016) and an 11.3% increase in the 
overall lifetime risk (Larney, Peacock, Mathers, Hickman, & Degenhardt, 2017). All 
other skin infections, diseases, abscesses and other acute traumas were grouped as either 
AIRI or IRID, depending on the study.  The majority of individuals studied reported at 
least one skin infection during their lifetime from a low of 23 percent (Ivan, Beek, Wand, 
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& Maher, 2015) to a high of 70 percent (Dahlman, Håkansson, Kral, Wenger, Ball, & 
Novak, 2017), and 15% reported persistent leg ulcers (Coull, Atherton, Taylor, & 
Watterson, 2014). Additionally, IDU was attributed to a 9.8% increase in the risk of 
sepsis, a 2% risk of bone infections, and a 3.9% lifetime risk of other infections not 
otherwise stated (Larney et al., 2017); a 35% risk of abscesses, 32% risk of phlebitis, 
23% of cellulitis, and a 4% risk of osteomyelitis (Lewer, Harris, & Hope, 2017).  
 
  
  
 
Table 1  
Studies Assessing Chronic and Acute Health Impacts of Individuals Who Inject Drugs 
Author(s) Aims Sample Measures Findings 
(Asgeirsson, Thalme, & 
Weiland, 2016) 
To assess the epidemiology, clinical 
characteristics, and mortality 
of S aureus endocarditis (SAE) 
in PWID in Stockholm, Sweden 
Method: Retrospective Study 
Eligibility: PWID treated for SAE at the 
Department of Infectious Diseases at the 
Karolinska University Hospital during January 
2004 to December 2013 
Size: 120 incidents 
Retrospective Data Analysis: medical records were 
reviewed, and microbiological data obtained to identify 
cases with IE caused by S aureus, clinical data, 
including information on intravenous drug use, and 
echocardiography reports were reviewed and the 
diagnosis of SAE was verified according to the 
modified Duke criteria 
 
SAE incidence among 
PWID 249 / 100,000 person 
years vs 0.76 / 100,000 in 
general population  
 (Aspinall et al., 2014) 
To quantify the efficacy of needle 
exchange programs in reducing 
new HIV infections 
Method: Review of 12 studies comprising at 
least 12,000 person-years 
Eligibility: Articles were quality assessed 
using the Newcastle-Ottawa (N-O) tool for 
cohort studies 
Size: 12,023 individuals 
Data Extraction: study date, location, design, selection 
criteria, sample size, person-years (PY) of follow-up, 
sex, age at recruitment, number of HIV seroconversions 
observed, HIV incidence in the group not exposed to 
NSP, HIV prevalence, definition of NSP exposure 
[amount of injecting equipment collected (volume), the 
percentage of injections where a clean needle and 
syringe was used (coverage), frequency of attendance at 
NSP or injecting during a time period when NSP was 
legal], definition of non-NSP exposure (relating to 
lower volume, coverage or attendance, or injecting 
during a time period when access to NSP was not 
legal), unadjusted/adjusted odds ratios (ORs), risk ratios 
(RRs) or hazard ratios (HRs) of HIV incidence 
associated with exposure to NSP 
 
5 reported a reduction in 
HIV 
 
4 cohort studies reported no 
evidence of association 
 
(Coull, Atherton, Taylor, 
& Watterson, 2014) 
To identify the range and extent of 
skin problems in IDUs 
Method: Cross-Sectional Survey 
Eligibility: IDU; 18 years or older 
Size: 200 individuals 
Interviews: utilizing face to face interviews individuals 
were asked about their IDU history; ulcers; lumps; 
track marks; abscesses; burns; broken skin; chronic 
wounds; and rashes 
60% reported at least 1 skin 
problem 
15% reported leg ulcers 
  
(Dahlman, Håkansson, 
Björkman, Alanko 
Blomé, & Kral, 2015) 
To investigate life time, past 12 
month and past 30-day 
prevalence for SSTI related to 
injection drug use 
Method: Cohort Study 
Eligibility: Current or previous injection drug 
use, and participation in Malmo SEP 
Size: 80 participants 
Interviews: “Have you [ever/past 12 months/past 30 
days] had an abscess or symptoms of skin and soft 
tissue infection (redness, swelling, pain, pus)?”, 
asked to discern difference between infection and 
irritation  
 
58% lifetime prevalence of 
SSTI 
30% past 12 months 
14% past 30 days 
(Dahlman et al., 2016)  
To determine if behavioral patterns 
related to skin and equipment 
hygiene are associated with 
increased risk for skin and soft 
tissue injuries 
Method: Cohort Study 
Eligibility: Recent IDU (30 Days); 18 Years or 
Older; Ability to consent  
Size: 201 Individuals 
77% Male 
 
Self-Reported Survey: Y/N single question about skin 
and soft tissue infection; follow-up questions about 
skin and equipment hygiene  
70% Reported lifetime 
prevalence of SSTI 
29% within 1 year 
11% within 30 days 
91% reported familiarity 
with symptoms of SSTI 
 
(Dunleavy et al., 2017) 
To determine the association 
between injecting behaviors and 
SSTI 
Method: Cross-Sectional Survey 
Eligibility: Current IDU; Fixed needle 
exchange site user 
Size: 2344 Individuals 
 
Self-reported Survey: Y/N single question about 
swelling, abscess, sore or open wound at injection 
site;   
Follow up: number of times injected in the past 30 
days; frequency of sharing; needle reuse  
28% SSTI within 1 year 
 
(Hagan, Pouget, & Des 
Jarlais, 2011) 
To meta-analyze the effects of risk-
reduction interventions on HCV 
seroconversion and identify the 
most effective intervention 
types 
Method: Systemic Review 
Eligibility:  reported HCV prevalence or 
incidence rates, measures of association, HIV-
HCV coinfection rates, HCV serological 
testing 
Size: 26 studies 
 
 
Systematic Review: Data collection was done through 
database searches and calls for data from HCV 
researchers 
Interventions using multiple 
combined strategies 
reduced risk of 
seroconversion by 75% 
(pooled relative risk, .25; 
95% confidence interval, 
.07–.83). Effects of single-
method interventions 
ranged from .6 to 1.6. 
 
  
(Hope, Ncube, Parry, & 
Hickman, 2014) 
To assess the prevalence of AIRI 
and other skin infections in 
IDUs 
Method: Cohort Study 
Eligibility: Participant self-referral, >15yo, 
have injected drugs within the past 4 weeks 
Size: 855 participants 
Logistical Regression: Participants underwent a 
computer-assisted interview, provided a dried blood 
spot sample (DBS) sample [tested for antibodies to 
the hepatitis B core antigen (anti-HBc), and hepatitis 
C (anti-HCV)] 
48% reported having 
redness, swelling and 
tenderness (RST) 
19% an abscess 
10% an open wound  
54% > 1 symptom 
45% sought medical advice 
9.5% hospitalized 
8.8% septicemia 
2.9% endocarditis 
 
(Ivan, Van Beek, Wand, 
& Maher, 2015)  
Examine the prevalence of 
injecting‐related injuries and 
diseases (IRIDs) and associated 
risk factors among people who 
inject drugs (PWID) 
Method: Retrospective cross‐sectional study 
Eligibility: All new KRC clients identified as 
having ever injected drugs who completed a 
clinician‐administered intake survey 
Size: 702 participants 
Interview and Clinical Survey: record lifetime and 
recent experience of IRIDs, cutaneous conditions 
(abscess, cellulitis, skin ulcer), ostheo‐articular and 
systemic infections (osteomyelitis, septic arthritis, 
septicaemia, endocarditis), vascular conditions 
(phlebitis, thrombosis, distal limb amputation) and 
other conditions (arrhythmia, other cardiac 
conditions, drug‐induced psychosis, convulsions and 
any other conditions) 
 
23% lifetime prevalence of 
IRID 
 
(Ivan, Rodgers, Maher, & 
Van Beek, 2016) 
To assess the burden of IRID 
amongst PWID  
Method: Before and After Survey 
Eligibility: PWID; Underwent serological 
testing between 6/11 and 3/12 
Size: 58 Individuals 
Self-Reported Survey: Baseline survey to explore 
lifetime IRID; Injection technique documented; Harm 
Reduction messages delivered 
16% reported not cleaning 
their hands prior to 
injecting 
38% reported applying a 
tourniquet correctly 
56% report not missing a 
vein 
33% report applying 
pressure longer than 1 
minute 
 
  
(Lake & Kennedy, 2016) 
To assess the potential negative 
health outcomes associated 
with injecting prescription 
opioids 
Method: PRISMA Review 
Eligibility: 18 years old or older; current IDU; 
inclusive of IRID 
Size: 31 studies 
Systematic Review: Various IRID identified and 
categorized; data reported by prevalence; health 
outcomes classified; drug use risk behavior and; 
adverse social exposers were excluded 
PWID are at risk of poorer 
general physical and mental 
health 
PWID are at greater risk for 
contracting HCV 
(Larney et al., 2017)  
To assess the prevalence of non-
viral IRID among people who 
inject drugs 
Method: PRISMA Review 
Eligibility: Contained data on prevalence of, or 
risk factors for, any non-viral IRID 
Size: 29 IRID Prevalence; 17 risk factors 
Systematic Review: Various IRID identified and 
categorized; data reported by prevalence 
6.1% Current month 
abscess 
32% Previous month 
abscess 
1.3% 6-12mo endocarditis 
0.5%-11.8% lifetime risk 
for endocarditis 
1% 6-12mo sepsis 
9.8% lifetime risk of sepsis 
2% lifetime risk of bone 
infections 
3.9% lifetime risk of other 
infections 
(Lewer, Harris, & Hope, 
2017) 
To assess skin, soft tissue, and 
vascular infections (SSTVI) in 
PWID using hospital 
admissions 
Method: Retrospective Chart Review 
Eligibility: 
Size: 63,671 participants 
Statistical Analysis: identified patients with “injecting-
related” infections as those with a relevant infection 
in the primary diagnostic field and “mental and 
behavioral disorders due to opioid use” in any other 
diagnostic field 
35% abscess 
32% phlebitis 
23% cellulitis 
4% septicemia 
4% osteomyelitis 
2% endocarditis 
0.2% necrotizing fasciitis 
 
(Lloyd-Smith et al., 
2008) 
 To characterize the risk factors for 
current injection related 
infections among IDUs 
Method: Longitudinal Analysis 
Eligibility: Must be SIF participant, must 
complete both intake and nurse-administered 
baseline questionnaires 
Size: 1065 individuals 
Cohort Study: Participants enrolled in study voluntarily 
based on usage of the SIF, Scientific Evaluation of 
Supervised Injection (SEOSI) 
Chance of having a skin 
infection: 
Female: 1.68 AOR 
Unstable housing: 1.49 
AOR 
Borrowing Syringe: 1.6 
AOR 
  
Requiring help injecting: 
1.42 
Injecting daily: 1.41 
 
(Lloyd-Smith et al., 
2009) 
Evaluate the factors associated with 
receiving cutaneous injection-
related infection (CIRI) care 
among PWID 
Method: Cohort Study 
Eligibility: Users of the downtown Vancouver 
SIF after their second visit 
Size: 1,080 participants 
Cohort Study: examined the total number of CIRI care 
events at the SIF reported by each participant, 
examined the sociodemographic and behavioral 
variables, collected as part of the baseline Scientific 
Evaluation of Supervised Injection 
questionnaire, stratified by whether receiving CIRI 
care was or was not obtained at the SIF 
22 per 100 person years for 
CIRI care 
Female: 1.87 AHR  
Unstable housing: 1.39  
Daily heroin injection: 1.52 
(Lloyd-Smith et al., 
2010) 
To investigate determinants of 
hospitalization for an AIRI or 
related infectious complication 
among a cohort SIF users 
Method: Data Regression 
Eligibility: Random recruitment of SIF 
participants, Scientific Evaluation of 
Supervised Injection (SEOSI) 
Size: 1083 participants 
 
Cohort Study: Referrals for treatment and wound care 
made at SIF by nurse, a linkage of SEOSI participant 
data, SIF data and St. Paul's Hospital inpatient data 
was performed 
Incidence Density for AIRI 
was 6.07 per 100 person 
years 
Length of Stay in Hospital 
when referred was 4 days vs 
12 days for non-referral  
(Nelson et al., 2011) 
To assess the size and scope of the 
risk of HCV with IDU 
worldwide 
Method: Systematic Review 
Eligibility: The number or prevalence of HCV-
infected IDUs in a country or subnational area 
were mentioned 
Size: 77 of 152 countries where IDU had been 
reported 
Data Analysis: Multiple reports were assessed for data 
on the prevalence of anti-HCV and HIV infection to 
assess HCV risk for IDUs 
60-80% of IDUs had anti-
HCV in 25 countries 
Over 80% had anti-HCV in 
12 countries 
(Phillips, Anderson, 
Herman, Liebschutz, & 
Stein, 2017) 
To assess the risk practices 
associated with IRID in PWID 
Method: Cross-Sectional Survey 
Eligibility: PWID; 18 years or older; self-
report substance use 3 days a week 
Size: 143 Individuals 
Self-Reported Survey: Demographics; HIV status; 
Substance Use; IRID history; ASI Drug Module 
administered; OSDQ administered; AUDIT-C 
administered; BIRSI administered 
 
65% report at least one 
IRID within 1 year 
 
(Pollini et al., 2010) 
Assess the prevalence of abscesses 
and soft tissue infections in 
IDUs 
Method: Cohort Study 
Eligibility: >18 years of age; having injected 
illicit drugs within the past month, as 
confirmed by inspection of injection stigmata 
Size: 623 participants 
Self-Reported Survey: Baseline and semi-annual 
survey, sociodemographic, behavioral, and contextual 
questions. Cross sectional survey on abscess history 
and treatment added at follow-up. Serological testing 
for HIV, HCV, and Syphilis 
46% reported ever having 
an abscess; 20% w/in 6 
months 
12% sought treatment  
  
(Spiller, Broz, Wejnert, 
Nerlander, & Paz-Dailey, 
2015) 
Monitor HIV prevalence and risk 
factors in PWID 
Method: Cross-Sectional Survey 
Eligibility: PWID within the previous 12 
months; 18 years or older 
Size: 10,002 individuals 
Self-Reported Survey: Participants offered anonymous 
HIV testing; administered a behavioral survey to 
establish risk factors and behaviors 
11% tested positive for HIV 
7% PWI Heroin only; 17% 
other or poly drug use 
30% shared syringes 
 
(Topp, Iversen, Conroy, 
Salmon, & Maher, 2008) 
Identify lifetime prevalence and 
predictors of self‐reported 
injecting‐related injuries and 
diseases (IRID) and/or 
injecting‐related problems (IRP) 
 
Method: Cross-Sectional Survey 
Eligibility: clients of 45 NSPs in Australia 
Size: 1,961 Participants 
Self-Reported Survey: participant indicated if they have 
any of five IRIDs (abscess; infection of an injecting 
site lasting more than one week; septicemia; 
thrombosis; endocarditis) and three IRPs (problems 
finding a vein; prominent scarring/bruising; swelling 
of hands or feet following injecting)  
 
69% reported IRID or IRP 
43% problems finding a 
vein 
4% endocarditis 
(Wurcel et al., 2016)  
To determine rates of 
hospitalization for endocarditis 
Method: Retrospective Chart Review 
Eligibility: Ages 15-64; Identified with IE; 
excluded with IE risk factors; included with 
IDU or HCV 
Size: 16,206 individuals 
Statistical Analysis: compared IDU-IE by year to 
observe trends in admission and discharge  
11-26% in hospital 
mortality rate 
Increase from 8% IDE-IE 
admission rate to 12.1% 
15-34yo increased from 
27.7% - 42% 
IDU IE increased from 
40.2% in 2000 to 68.9% in 
2013 in white males 
 
(Zibbell et al., 2018) 
To compare national rates of acute 
HCV to PWID 
Method: Systematic Review 
Eligibility: Positive HCV antibody test; IDU 
Size: Nationwide 
Data Analysis: Utilizing the National Notifiable 
Disease Surveillance System to determine rates of 
HCV in the general population and control for IDU 
Annual incidence rate of 
acute HCV infection 
increased more than 2-fold 
(from 0.3 to 0.7 
cases/100 000) from 2004 
to 2014 
Opioid IDU increased risk 
4-fold 
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Discussion: Literature Review 
Ever since the Reagan administration’s proclamation of a “War on Drugs,” punitive and 
criminal justice measures have been enacted in various degrees in an attempt to find a solution 
for substance use and the community level impact of substance use (Aspinall et al., 2014; 
Binswanger & Gordon, 2016; Dunleavy, Munro, Roy, Hutchinson, Palmateer, Knox, Goldberg, 
& Taylor, 2017; Fernandes, Cary, Duarte, Jesus, Alarcão, Torre, Costa, Costa, & Carneiro, 2017; 
Goldstein et al., 2015; Grau, Arevalo, Catchpool, & Heimer, 2002; Hagan et al., 2011; Harris, 
Brathwaite, McGowan, Ciccarone, Gilchrist, McCusker, O’Brien, Dunn, Scott, & Hope, 2018; 
Hellard, Rolls, Sacks-Davis, Robins, Pattison, Higgs, Aitken, & McBryde, 2014; Hooton, 2015; 
Hope, Kimber, Vickerman, Hickman, & Ncube, 2008; Ivan et al., 2016; Jette, 2018; Lim, Vos, 
Flaxman, Danaei, & Shibuya, 2012; Martin, Hickman, Hutchinson, Goldberg, & Vickerman, 
2013; McNeil & Small, 2014; Metrebian et al., 2015; Nelson et al., 2011; Patel, Foote, Duwve, 
Chapman, Combs, Fry, Hall, Roseberry, Brooks, & Broz, 2018; Phillips, Stein, Anderson, & 
Corsi, 2012; Platt et al., 2018; Smith, Robinowitz, Chaulk, & Johnson, 2014; Stancliff et al., 
2015; Wallace, Barber, & Pauly, 2018; Werb, 2018; Wiessing et al., 2017; Wilson, Donald, 
Shattock, Wilson, & Fraser-Hurt, 2015; Wood, McKinnon, Strang, & Kendall, 2012). However, 
as the opioid crisis continues to grow in America, it has become obvious to many that this 
strategy has failed. While addressing the issue of substance use, the normative view is to always 
assist an individual with moving toward recovery and abstinence of all substances. However, the 
harm reduction approach to substance use rejects this notion of abstinence and assumes that there 
will always be some level of recreational substance use and misuse (Hooton, 2015). Therefore, 
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the goal should be to reduce the harms associated with substance use, relative to the stated public 
policy of the “War on Drugs” (Marlatt, Blume, & Parks, 2001). Since there will always be 
substance use, the focus should be on harm reduction measures to reduce the burden of infectious 
disease, and on treatment to help individuals with their goals.  This two-pronged approach to 
substance misuse, and substance use, will likely have a better community level outcome than 
simply waging war on a public health issue.  
  
Harm Reduction 
By assisting persons who inject drugs with basic sanitation and safe injection techniques 
health/behavioral health practitioners can reduce the number of missed veins and skin infections 
(Ivan et al., 2016).  A missed vein could potentially develop into an abscess or a skin infection, 
which, if left untreated, could migrate to the heart and develop infective endocarditis.   People 
who inject drugs consistently reported skin infections 28-70% (Coull et al., 2014; Dahlman, 
Håkansson, Björkman, Blomé, & Kral, 2015; Dunleavy et al., 2017; Phillips, Anderson, Herman, 
Liebschutz, & Stein, 2017) which can also develop into abscesses or other skin lesions. If those 
infections pass beyond the skin, are left untreated, conditions can progress to sepsis and be fatal. 
Additionally, IDU increases the absolute risk of complex bone infections by 2%, which can 
cause significant treatment issues and distress in the individual (Larney et al., 2017).  
Basic injection supplies could potentially consist of alcohol swabs for cleaning the skin properly, 
individual use sterile water packets, and clean needles. These supplies reduced the spread of HIV 
in five cohort studies (Aspinall et al., 2014), and could be extrapolated to produce similar results 
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in reducing the spread of HCV, reducing the incidence rates of skin infections and infective 
endocarditis.  
Infectious Disease 
The community burden of infectious disease due to IDU is also enormous; over a 12-
month period at a single hospital in Florida, it cost the state $11.4 million to treat injection 
related injuries and infections (Tookes, Diaz, Li, Khalid, & Doblecki-Lewis, 2015). Considering 
that illicit substance use is an ongoing issue, this cost is an ongoing expense; therefore, it could 
be expected to continue or increase year to year. The burden of this cost is placed on the 
community itself to bear, as many individuals with significant substance use problems may not 
have insurance or may be on state insurance.  Individuals on Medicaid have their insurance paid 
by the state, therefore it is the rest of the community that bears the cost of these infections. By 
targeting the community of PWID with tailored harm reduction services like clean needles to 
prevent sharing and the spreading of disease, sterile supplies, safe injection techniques, basic 
wound care, and overdose prevention supplies it could potentially translate into a significant cost 
savings for the state. Additionally, it is not only a cost savings measure.  According to the 
NASW Code of Ethics, “Social workers respect the inherent dignity and worth of the person” 
(Levy, 2017); therefore, it is a professional guiding principle of the Social Work profession that 
each individual has intrinsic worth and value. 
Critique 
 While every effort is made to be as thorough as possible when conducting a systematic 
literature review, the reliance on published studies when focusing on a singular issue has its own 
limitations. Not every study takes into account various social determinants of health (SDOH), 
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which are the conditions of the places where individuals live, work, and play and can have a 
significant impact on an individual’s health (Adler, Glymour, & Fielding, 2016).  These studies 
use varied measures, and control for different variables. Additionally, while each study contained 
within the literature review is inherently valuable for adding to the body of literature, because of 
the social and economic variations of each location and community studied, there are an 
unknown number of factors influencing the health of the participants. While it’s possible to draw 
preliminary conclusions from the data, it is impossible to assess causal factors. 
 
Study Two - Secondary Data Analysis 
 
Background 
Subsequent to analyzing the data from the comprehensive literature review, a research 
concept was proposed to study the local population of IDU and attempt to assess the frequency 
and prevalence of AIRI. The goal of the study was to ascertain whether or not PWID in Phoenix 
suffered from the same acute skin issues, at the same prevalence rates, as PWID in other areas. 
While overdose is the most severe consequence of IDU, it is not the only consequence. A history 
of IDU can cause skin and soft tissue damage, endocarditis, septicemia, and chronic illnesses like 
HCV and HIV (Harris et al., 2018). Even if individuals avoid the most severe health 
consequences of IDU, death or HCV/HIV, they can still potentially be left with a lifetime of 
physical scarring. Ultimately, one of the primary goals of harm reduction is to protect the 
individuals’ health and safety until such a time that they make the choice to make changes in 
their lives.  And harm reduction need not be partaken in for solely moral reasons, it is also cost 
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effective and provides benefit to the community (Wilson et al., 2015). By assessing the 
prevalence rates of AIRI, and then working to develop interventions to address those 
complications, better long-term outcomes can provide for individuals in communities. For 
instance, an individual who uses substances chronically, may develop skin scarring from 
abscesses or other skin infections. These abscesses can impact the individual’s self-esteem, 
reduce their employability, or lead to depression and anxiety. Therefore, discovering the 
prevalence of these acute injuries, and the impact on the individual’s health can provide valuable 
information for researchers and clinicians involved in harm reduction and substance use.  
 
Research Questions 
Research Question One: What relationship, if any, exists between injection drug use and 
skin and soft tissue infections? 
The null and alternate hypotheses for this research question were as follows: 
Null Hypothesis: There is no significant correlation between injection drug use and skin and soft 
tissue infections. 
Alternate Hypothesis: There is a significant correlation between injection drug use and skin and 
soft tissue infections. 
 
Research Question Two: What relationship, if any, exists between injection drug use and 
reusing injection equipment? 
The null and alternate hypotheses for this research question were as follows: 
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Null Hypothesis: There is no significant correlation between injection drug use and reusing 
injection equipment. 
Alternate Hypothesis: There is a significant correlation between injection drug use and reusing 
injection equipment.  
 
Research Question Three: What relationship, if any, exists between reusing injection 
equipment and sanitation measures; such as, hand washing and use of antiseptic? 
The null and alternate hypotheses for this research question were as follows: 
Null Hypothesis: There is no significant correlation between reusing injection equipment and 
sanitation measures; such as, hand washing and use of antiseptic. 
Alternate Hypothesis: There is a significant correlation between reusing injection equipment and 
sanitation measures; such as, hand washing and use of antiseptic.  
 
Research Question Four: What relationship, if any, exists between sharing needles and 
using sanitation measures; such as hand washing and use of antiseptic? 
The null and alternate hypotheses for this research question were as follows: 
Null Hypothesis: There is no significant correlation between sharing needles and using sanitation 
measures; such as hand washing and use of antiseptic. 
Alternate Hypothesis: There is a significant correlation between sharing needles and using 
sanitation measures; such as hand washing and use of antiseptic.  
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Research Question Five: What relationship, if any, exists between sharing needles and 
sharing other injection supplies such as cookers, spoons, cotton, or tourniquets? 
The null and alternate hypotheses for this research question were as follows: 
Null Hypothesis: There is no significant correlation between sharing needles and sharing other 
injection supplies such as cookers, spoons, cotton, or tourniquets. 
Alternate Hypothesis: There is a significant correlation between sharing needles and sharing 
other injection supplies such as cookers, spoons, cotton, or tourniquets. 
 
 
Methods 
Participants were recruited from the community of persons who use drugs (PWUD) at 
community syringe exchange sites in Phoenix, Arizona. Consenting participants (> 18 years of 
age) were screened to verify eligibility for inclusion. Participants were determined to be eligible 
if they self-reported currently using opioids. Exclusion criteria included the obvious presence of 
severe cognitive or psychiatric impairment (i.e., not oriented to person, place, and time) and 
unable to speak and understand the English language (resources limited the ability for the 
research team to translate materials). Electronic gift cards for survey research were available to 
eligible remote participants if necessary. Initially, researchers conducted a semi-systematic 
literature review to evaluate empirical research related to first responders and engagement with 
community members. Further, researchers explored validated instruments that evaluate study 
constructs including addiction severity, health status, treatment history, health disparity, and 
engagement. Ultimately, researchers constructed an instrument with less than 20-minute 
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response time. Initially, construct validity was assessed by piloting the instrument in 
collaboration with project experts and community partners. Once the instrument had established 
face validity, a web-based survey using Qualtrics was created, a software that enables users to 
collect and analyze survey data.  
Quantitative Measures 
• Demographics were assessed with a brief set of questions that included items such as age, 
sex, race/ethnicity, education, employment, marital and family status, and income. 
• Addiction Severity –The primary outcome of interest for substance use frequency was 
based on participant self-reports on the number of days (during the past three months) 
that they have used any drugs or alcohol. The Short Inventory of Drug/Alcohol Problems 
(SIP-A/D) (Kiluk, Dreifuss, Weiss, Morgenstern, & Carroll, 2013) was used to assess 
problematic use patterns. Combined drug/alcohol problem scores were used to create an 
index of severity. 
• Treatment History- The Treatment Services Review focused on services for seven 
potential problem areas: medical status, employment, support, drug use, alcohol use, legal 
status, family/social status, and psychiatric status. Participants were asked (using an 
adapted self-report instrument) about the services that they received in the past 90 days 
including (but not limited to) emergency room visits and instances of incarceration 
(McLellan, Alterman, Cacciola, Metzger, & O’Brien, 1992).  
• Self-reported Health Status- Using the RAND Measures of Quality of Life SF-36 Survey 
Instrument (Hays & Morales, 2001), researchers assessed multiple measures of quality of 
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life, including physical, mental and emotional health. Participants were asked about 
various aspects of their health.  
• Health Disparity Questions- To assess health disparities, researchers mirrored the 
questions used in the AZ Behavioral Risk Factor Surveillance System 2017 (AZBRFSS; 
Arizona Department of Health Services, 2017).  
• Questionnaire. Items specifically focused on Section 1 of AZBRFSS: Health Status, 
Section 2: Healthy Days - Health-Related Quality of Life, Section 6: Chronic Health 
Conditions, State-Added Section 6: Prescription Drug Abuse, State-Added Section 7: 
Substance Abuse, and State-Added Section 11: Opioid Use / Chronic Pain. By utilizing 
parts of the same instrument used by the Arizona Department of Health, data were able to 
be compared to the data gathered for Arizonans and FR-BRIEF SITD participants. 
Data was collected from Qualtrics and analyzed using SPSS, focusing on descriptive statistics 
including frequencies and crosstabs and, bivariate correlation.  
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Results 
The survey of Shot in the Dark community participants generated a large amount of data 
on the individual demographics of the population. The average age of the survey participants was 
38 years ago (Table 2). Of participants, 37.1% reported their health as being good or better, with 
41% reporting it as average or worse, with 2.9% reporting their health to be Terrible (Table 2). 
The reported gender of the participants was skewed towards male (53.3%) with female being 
reported as 35.2%, and Two Spirit and Agender at both 1% (Table 2). Nearly one quarter of 
survey participants reported completing at least some college (23.8%), and 19% reported not 
finishing high school (Table 2). 
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Table 2 
Demographics of Individuals Surveyed 
 
n = 105 
Total 
n % 
Health status 
Excellent, good 
Average, poor 
Terrible 
 
39 
43 
3 
 
37.1 
41.0 
2.9 
Age (mean) 38  
Gender 
Male 
Female 
Two Spirit 
Agender 
 
56 
37 
1 
1 
 
53.3 
35.2 
1 
1 
Race 
    American Indian or Alaskan Native 
Black or African American 
Hispanic, Latino or Spanish 
Native Hawaiian or Other Pacific Islander 
White (Not Hispanic) 
 
5 
9 
16 
1 
70 
 
4.8 
8.6 
15.2 
1 
66.7 
Education 
Did not complete High School 
Graduated High School 
GED 
Technical or Professional School 
Some College 
Graduated College 
 
20 
22 
20 
7 
25 
6 
 
19 
21 
19 
6.7 
23.8 
6 
 
Over half of all study participants reported no chronic medical problems (57.1%), with the most 
common reported problems being: more than one chronic health condition (13%), Hepatitis C 
(10%), Abscesses (8.0%) and Back Pain (4.0%) (Appendix: Figures 18 and 19). The majority of 
study participants reported injecting their drug of choice (72.4%), with over half (59%) reporting 
that they injected their DOC the same day as the survey (Table 3).   Needle reuse was higher than 
half (61%) but sharing of needles was significantly lower (21%); however, sharing of supplies 
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other than needles was reported more frequently (34.3%) (Table 3). Participants reported that 
heroin was their overall Drug of Choice (DOC) (58.1%) with amphetamines coming in second 
with nearly half as many (12.4%) participants reporting it as their DOC (Table 3). Most 
participants reported preferring to inject into a vein (65.7%), followed by into the muscle 
(11.4%) at a far lower frequency of response. The location of preference for injection on the 
body was spread fairly evenly overall, with responses including: Lower arm (13.3%), inside the 
elbow (12.4%), upper arm (11.4%), hand or leg (both at 7.6%), and “wherever I can” at (23.8%) 
(Table 2).  Most participants reported positive personal hygiene, with respondents answering if 
they washed their hands before injecting stating Probably or Definitely Yes 51.4% of the time, 
cleaning the skin with antiseptic 49.5%, cleaning the skin with soap and water 37.2%, and using 
new unshared sterile water 50.5% (Tables 3, 4, 5, and 6).  
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Table 3  
Chronic Medical Issues and Injection Habits 
 
 
 
n = 105 
Total 
n % 
Do you have any chronic medical problems?  
Yes 
No 
 
38 
60 
 
36.2 
57.1 
Do you inject your drug of choice?  
Yes 
No 
 
76 
18 
 
72.4 
17.1 
When was the last time you injected your DOC? 
Today 
Yesterday 
This Week 
Last Month 
Within the last 30 days 
 
62 
10 
6 
1 
4 
 
59.0 
9.5 
5.7 
1.0 
3.8 
Have you reused any of your injection equipment?  
Yes 
No 
 
64 
23 
 
61.0 
21.9 
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Table 4  
Skin and Injection Hygiene Data 
 
 
n = 105 
Total 
n % 
Do you wash your hands first?  
Definitely Yes, Probably Yes 
Might or might not 
Probably Not 
 
54 
19 
14 
 
51.4 
18.1 
13.4 
Do you clean the skin with antiseptic?  
Definitely Yes, Probably Yes 
Might or might not 
Probably Not, Definitely Not 
 
52 
18 
18 
 
49.5 
17.1 
17.1 
Clean the skin with soap and water?  
Definitely Yes, Probably Yes 
Might or might not 
Probably Not, Definitely Not 
 
39 
26 
22 
 
37.2 
24.8 
20.9 
Use new sterile water? (n, %) 
Definitely Yes, Probably Yes 
Might or might not 
Probably Not, Definitely Not 
 
53 
18 
16 
 
50.5 
17.1 
15.3 
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Table 5  
Injection Site Preference 
 
 
n = 105 
Total 
n % 
What area of the body do you frequently use as your injection site?  
Inside of the elbow 
Hand 
Upper Arm 
Lower Arm 
Leg 
Groin 
Neck 
Foot 
Wherever I can 
 
13 
8 
12 
14 
8 
1 
4 
2 
25 
 
12.4 
7.6 
11.4 
13.3 
7.6 
1.0 
3.8 
1.9 
23.8 
What area of the body do you frequently use as your injection site? 
Into a vein 
Into the muscle 
Under the skin 
Wherever I can 
 
69 
12 
1 
10 
 
65.7 
11.4 
1.0 
9.5 
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Table 6  
Needle Sharing and Drug of Choice 
 
 
n = 105 
Total 
n % 
Have you shared needles in the past 30 days?  
Yes 
Maybe 
No 
 
22 
8 
57 
 
21.0 
7.6 
54.3 
Have you shared injection equipment other than needles in the past 30 days?  
Yes 
Maybe 
No 
 
 
36 
9 
42 
 
 
34.3 
8.6 
40.0 
What is your preferred drug of choice?  
Alcohol 
Heroin 
Methadone 
Other Opiates/Analgesics 
Cocaine 
Amphetamines 
Cannabis 
Hallucinogens 
 
3 
61 
3 
2 
2 
13 
6 
1 
 
2.9 
58.1 
2.9 
1.9 
1.9 
12.4 
5.7 
1.0 
 
 
Discussion: Secondary Data Analysis 
This research was conducted with the original hypothesis being that individuals who 
inject drugs would likely suffer from higher rates of skin and soft tissue infections (AIRI). The 
theory supporting this hypothesis was that breaking the skin barrier and injecting a foreign and 
highly acidic substance (Ciccarone & Harris, 2015) into the body would be likely to introduce 
bacteria and cause AIRI. However, the evidence from this cohort was unable to support this 
hypothesis and the hypothesis is rejected. Only 8.0% of respondents claimed to have problems 
with abscesses (Appendix: Figure 19), and only 36.2% stated they had any chronic medical 
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condition (other than addiction itself) at all (Table 2). These data seemingly contradict the 
commonly held belief that PWID suffer from chronic poor health overall as a result of their 
substance use; however, due to the small sample size, and the population surveyed, it is entirely 
possible that the data are outliers.  
Pearson r correlations were used due to it being the commonly accepted “gold standard” 
for correlations (Laurent, 1998). However, there are some limitations to its usage. Firstly, 
correlations cannot be used to show a cause-and-effect relationship, it merely shows that two 
items are correlated. Secondly, outliers can have a significant effect by pulling the line of best fit 
formed by the correlation too far in one direction. Nevertheless, Pearson  r is still the most 
widely used and commonly accepted correlation statistic for measuring the degree of relationship 
between two or more linearly related variables.  
 
Potential Protective Factors 
While there is inherent risk in injecting substances, there are also ways to mitigate some 
of the risk and lower the chance of negative outcomes. One item that stood out as interesting and 
could likely explain the low prevalence rates of AIRI was the high uptake of beneficial skin 
hygiene routines by PWID. Most of the individuals reported washing their hands (51.4%), 
cleaning the skin with alcohol or other antiseptic (49.5%), using soap and water to wash their 
skin before injecting (37.2%), and using new, unshared, sterile water (50.5%); this trend could 
easily reduce the frequency and severity of acute skin infections. An additional factor that could 
likely explain the findings is the location of the data collection itself. Over half (54.3%) of the 
participants of the survey reported that they had not shared needles in the past 30 days. This 
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figure could be explained due to the fact that the data were gathered from individuals who were 
participating in the local Phoenix syringe access program (SAP). Along with new needles, and 
medical supplies, participants were also offered information on safer injection techniques from 
these SAPs. Harm reduction kits could contain new cookers, tourniquets, cotton balls and alcohol 
swabs. Basic medical supplies were often limited versions of these kits and could include alcohol 
swabs and literature on safer injection techniques. It can be posited that individuals who would 
frequent a syringe exchange program to get new needles and safer injection information, are 
using those basic medical supplies to clean their skin before injecting, and that is effectively 
reducing the incidence rates of abscesses and other AIRI. Unfortunately, at the time of this study, 
the full harm reduction kits were no longer being provided due to funding limitations. However, 
during the data collection period of the study, limited medical supplies were still somewhat 
available, and participants were offered information about safer injection techniques. The past 
availability of these products could potentially have been a positive influence on AIRI and 
reduced the number and frequency of skin and soft tissue infections. It is impossible to note if 
these limited supplies, and the often frequent fluctuations in the available quantity of clean 
needles available to participants, had any effect on the reported frequency of AIRI.  
 
Injection Drug Use and Equipment Reuse  
The second research question was, what relationship if any, exists between persons who 
inject drugs and the reuse of injection equipment. The null hypotheses stated: there is no 
significant correlational between injection drug use and the reuse of injection related equipment. 
Descriptive statistics and correlations were calculated to analyze the data.  
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Table 7  
Injection Drug Use and Injection Related Equipment Reuse 
 Reuse 
Injection 
Equipment 
New sterile 
water 
Inject DOC .319** -.222* 
(*)   Correlation is significant at the 0.05 level (2-tailed). 
(**) Correlation is significant at the 0.01 level (2-tailed). 
 
Table 7 displays the findings in relation to research question two. Each of the items were 
correlated using Pearson r. There was a significant correlation with the reuse of injection 
equipment and the use of new sterile water and injection drug use. Based on the overall results of 
the analysis and individual analyses the null hypothesis was rejected. With the exception of the 
use of sterile water there was a strong correlation. 
 
Injection Equipment Reuse and Sanitation Measures   
The third research question was, what relationship if any, exists between reusing injection 
equipment and sanitation measures; such as hand washing and use of antiseptic. The null 
hypotheses stated: there is no significant correlational between reusing injection equipment and 
sanitation measures; such as hand washing and use of antiseptic. Descriptive statistics and 
correlations were calculated to analyze the data.  
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Table 8  
Injection Equipment Reuse and Skin Hygiene 
 New sterile 
water 
Wash hands Antiseptic 
use 
Soap and 
water 
Reused Injection 
Equipment  
-.123 -.137 -.167 .009 
 (*)   Correlation is significant at the 0.05 level (2-tailed). 
(**) Correlation is significant at the 0.01 level (2-tailed). 
 
Table 8 displays the findings in relation to research question three. Each of the items 
were correlated using Pearson r. There was no significant correlation with any of the items. 
Based on the overall results of the analysis and individual analyses the null hypothesis was 
accepted.  
Needle Sharing and Sanitation Measures 
The fourth research question asked, what relationship if any, exists between sharing 
needles and sanitation measures; such as hand washing and use of antiseptic. The null 
hypotheses stated: there is no significant correlational between sharing needles and sanitation 
measures; such as hand washing and use of antiseptic. Descriptive statistics and correlations 
were calculated to analyze the data.  
 
Table 9  
Sharing Needles and Skin Hygiene 
 New sterile 
water 
Wash 
hands 
Antiseptic 
use 
Soap and 
water 
Sharing needles -.404** -.236* -.282** -.204 
 (*)   Correlation is significant at the 0.05 level (2-tailed). 
(**) Correlation is significant at the 0.01 level (2-tailed). 
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Table 9 displays the findings in relation to research question four. Each of the items were 
correlated using Pearson r. There was a significant correlation with the sharing of needles and 
the use of sterile water, the sharing of needles and washing hands, and the sharing of needles and 
the use of antiseptic. Based on the overall results of the analysis and individual analyses the null 
hypothesis was rejected. With the exception of the use of soap and water, there was a strong 
correlation between needle sharing and skin hygiene.  
Needle Sharing and Equipment Sharing 
The fifth and final research question was, what relationship if any, exists between sharing 
needles and sharing other injection supplies such as cookers, spoons, cotton, tourniquets, and 
water. The null hypotheses stated: there is no significant correlational between sharing needles 
and sharing other injection supplies such as cookers, spoons, cotton, tourniquets, and water. 
Descriptive statistics and correlations were calculated to analyze the data.  
Limitations 
 While the data from this study is interesting, and contributes to the overall knowledge 
about substance use, there are limitations to what can be inferred from the results. First, due to 
the limitations of the study design, causation cannot be assumed; all results are correlations only 
and do not take into account cofounding variables. Secondly, this data cannot be generalized 
across the entire population, since disparities in race cannot be accounted for. Due to the small 
sample size, and the limited information gathered, it is impossible to know if the results are 
indicative of what would be seen in a larger population study. Additionally, due to the variability 
in funding that Shot in the Dark receives, harm reduction supplies are not always available to 
participants and the supplies vary at easy site. This unpredictability adds an additional variable to 
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the data that the researchers are unable to control for. Another variable with the Shot in the Dark 
supplies, is the lack of educational materials in Spanish. Arizona has a very significant Hispanic 
population, some of which might have limited ability to speak and read English. Therefore, the 
lack of materials in alternate languages might limit the population they are able to serve, and 
therefore artificially skew the sample.  
 Studies done concerning the population of persons who inject drugs are frequently 
concerning HIV and HCV. While the AZ BRFSS did inquire about HIV status, the AZ-BRIEF 
did not. Since this data analysis was focused primarily on acute skin infections and acute disease, 
rather than chronic medical conditions, the question concerning HIV status was not asked. 
Hepatitis C was only addressed in this study due to multiple participants indicating their HCV 
status in their survey responses. However, while no respondents indicated a positive HIV status 
in their survey response, no specific conclusion can be drawn from that. Therefore, since this 
study did not specifically inquire about HIV status, and since it was not indicated in any of the 
survey responses, it was not included in the data analysis.  Another limitation of the AZ-BRIEF 
study is the lack of study materials in Spanish. Similar to the limitation with Shot in the Dark 
educational materials, the lack of Spanish language survey materials is inherently limiting 
regarding the population surveyed.  
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Table 10  
Sharing Needles and Sharing Equipment and Supplies 
 Sharing injection 
equipment 
New sterile 
water 
Sharing needles .355** -.404** 
 (*)   Correlation is significant at the 0.05 level (2-tailed). 
(**) Correlation is significant at the 0.01 level (2-tailed). 
 
Table 10 displays the findings in relation to research question five. Each of the items 
were correlated using Pearson r. There was strong correlation with the sharing of needles and the 
other supplies. Based on the overall results of the analysis and individual analyses the null 
hypothesis was rejected.  
Conclusion 
The data from the comprehensive literature review was not born out by the data in our 
small study; the data from the literature review showed that AIRI is fairly common in PWID, 
however, this study did not show a correlation between IDU and AIRI. It is impossible to 
extrapolate the reason for this, as there are too many unaccounted-for variables in the process. 
However, it would be safe to assume that the syringe exchange sites contributed to greater 
overall health implications in the participants who are able to access them. This conclusion is 
borne out by the high rates of usage of hygiene supplies by the participants; alcohol swabs and 
sterile water are commonly utilized by the participants of the survey, as are items provided by 
the syringe access sites where the studies were conducted. The sharing of needles had a strong 
positive correlation with the sharing of other injection equipment other than needles, and a strong 
negative correlation with using new sterile water. Thus, one can conclude that persons who share 
needles, are also likely to share other supplies and not use sterile water for their injection 
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practices. There was also a strong positive correlation between individuals who injected their 
drug of choice, and the reuse of needles. This underlines the need for a higher availability and 
easier access to new sterile syringes.  
 The findings from the literature review underlie the need for solutions to substance use; 
the cost to communities is shown both in the toll it takes on members of the community in illness 
and injury, and in the fiscal cost of treating acute injection related injuries that can be significant. 
Simple measures such as providing clean needles, alcohol swabs, and sterile water could address 
both the issue of acute infections and the fiscal cost of treating abscesses and wounds in city and 
county emergency rooms. One anomaly in the data showed up during the study that bears 
addressing; while the participant use of alcohol swabs and sterile water was relatively high 
(49.5% and 50.5%, respectively) the rate of skin washing with soap and water remained 
significantly lower (37.2%). While it is impossible to know the reason for this discrepancy, 
researchers considered that lack of access to restrooms (public or private) or homelessness might 
play a factor. Lack of access to warm running water and soap, due to lack of stable housing 
would make it more difficult to wash one’s hands. Additionally, the alcohol swabs are small, pre-
packaged, and easily portable. The ability for an individual who does not have stable housing to 
carry though around with them is far easier, as they can be stored in pockets or in a backpack, 
unlike running water. In conclusion, while the data from this small cohort study did not align 
well with the data from the literature, there was still a large amount of valuable data gathered and 
conclusions that could be drawn.  
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Practical Implications 
The goal of harm reduction social work is to provide tools and services to individuals 
engaged in potentially harmful activities that reduce their personal harm from that activity 
(Dunleavy et al., 2017; Stancliff et al., 2015; Wilson et al., 2015). This recognizes that every 
person has dignity, and inherent value, and that simply suffering from a substance use disorder 
should not be a reason to not provide help and support. While the research conducted did not 
show that there is a prevalence of AIRI in PWID, it does show a correlation between the usage of 
harm reduction and the negative instances of these skin and tissue infections. Nearly half of all 
participants engaged in healthy skin hygiene practices, which could likely have reduced their 
chances of infection significantly.   
Encouraging healthy hygiene practices and expanding access to these harm reduction 
practices could potentially expand that effort and assist more individuals in protecting their lives 
and health. For instance, expanding access to syringe access programs could reduce the sharing 
of needles and reduce infections; expanding access to harm reduction kits (sterile cotton balls, 
alcohol or iodine swabs, sterile water, new cookers, and new tourniquets) could additionally 
reduce the risk of skin infections. Expanding public health classes on the topics of skin hygiene 
and wound care could also provide a net public health benefit, as well as a significant benefit to 
the individual’s quality of life.  
 Of the four research questions that were asked, the strongest correlation was between 
injection drug use and reusing needles and sharing needles and sharing other injection 
equipment. It can be inferred that persons who are likely to share their needles are also likely to 
share the rest of their equipment, and that persons who inject drugs are likely to also reuse their 
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supplies. Reusing needles should be discouraged, as they quickly become dull and are more 
likely to tear the skin and veins and cause additional trauma to the user’s body. A simple and 
practical solution to this problem is making it easier for PWID to access clean, sterile, needles, 
and working to reduce the stigma that individuals face when purchasing needles from 
pharmacies. While reducing the stigma might be easier said than done, since as a society it is all 
too easy to pass judgment on individuals, a person who can access new sterile needles is far less 
likely to reuse them, and therefore far less likely to suffer secondary trauma from the reuse of 
those needles.  
Another potential harm in needle reuse is that of bacteria. While the substances the user is 
injecting were likely cooked or heated up prior to the initial injection, there is a potential for 
residue to remain within the barrel of the syringe itself and to contaminate further doses. This 
residue could harbor harmful pathogens, and since it is not cooked a second time, would be 
introduced into the user’s bloodstream. This topic might be a valuable avenue of further research 
in the future; do persons who reuse needles have a higher instance of skin and blood infections 
than persons who do not? 
Additionally, the sharing of needles should be discouraged, as it is an easy way to share 
communicable diseases. HIV and Hepatitis C are both easily transmitted via blood contact and 
injection drug use and reducing the vector for transmission by reducing needle sharing is a 
valuable public health goal for harm reduction social workers. However, disease transmission 
can occur with more than just needle sharing, and the sharing of other injection equipment 
highlights how this might not occur to an individual. If multiple people are using the same bottle 
of water, they can mix microscopic droplets of blood into the water and contaminate it for each 
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other. The same issue can occur with multiple people sharing cookers for their substance; by 
sharing these items, they increase the likelihood of cross-contamination and increase their risk 
for communicable diseases.  
By practicing basic hygiene, increasing access to education, and promoting the expansion 
of basic services and supplies for persons who inject drugs, their overall quality of life can be 
improved and protected, and their incidence of infection and illness can be reduced. While the 
act of handing out alcohol swabs might not seem like it would have a substantial impact in and 
individual’s life, it could prevent potentially life-threatening infections or enable an individual to 
find a better job. Increasing funding and support for syringe access programs could reduce or 
eliminate injection drug users as a vector for the transmission of HIV and HCV, as well as 
reduce the risk of abscesses and other skin infections. The benefit to these basic services can be 
significant if approached from a harm reduction perspective.  
 
  
42 
 
REFERENCES 
 
Adler, N. E., Glymour, M. M., & Fielding, J. (2016). Addressing Social Determinants of Health 
and Health Inequalities. JAMA, 316(16), 1641. https://doi.org/10.1001/jama.2016.14058 
 
Arizona Department of Health Services. (2017). Arizona Behavioral Risk Factor Surveillance 
System. Retrieved from https://www.azdhs.gov/preparedness/public-health-
statistics/behavioral-risk-factor-surveillance/index.php 
 
Asgeirsson, H., Thalme, A., & Weiland, O. (2016). Low mortality but increasing incidence of 
Staphylococcus aureus endocarditis in people who inject drugs: Experience from a Swedish 
referral hospital. Medicine, 95(49), e5617. https://doi.org/10.1097/MD.0000000000005617 
 
Aspinall, E. J., Nambiar, D., Goldberg, D. J., Hickman, M., Weir, A., Van Velzen, E., … 
Hutchinson, S. J. (2014). Are needle and syringe programmes associated with a reduction in 
HIV transmission among people who inject drugs: a systematic review and meta-analysis. 
International Journal of Epidemiology, 43(1), 235–248. Retrieved from 
https://academic.oup.com/ije/article/43/1/235/734951 
 
Binswanger, I. A., & Gordon, A. J. (2016). From risk reduction to implementation: Addressing 
the opioid epidemic and continued challenges to our field. Substance Abuse, 37(1), 1–3. 
https://doi.org/10.1080/08897077.2015.1134152 
 
Centers for Disease Control and Prevention (CDC). (2017). Opioid Overdose: Prescribing Data. 
Retrieved October 26, 2018, from https://www.cdc.gov/drugoverdose/data/prescribing.html 
 
Ciccarone, D., & Harris, M. (2015). Fire in the vein: Heroin acidity and its proximal effect on 
users’ health. International Journal of Drug Policy. 
https://doi.org/10.1016/j.drugpo.2015.04.009 
 
Coull, A. F. A. F., Atherton, I., Taylor, A., & Watterson, A. E. A. E. (2014). Prevalence of skin 
problems and leg ulceration in a sample of young injecting drug users. Harm Reduction 
Journal, 11(1), 22. https://doi.org/10.1186/1477-7517-11-22 
 
Crane, E. H. (2013). Emergency department visits involving narcotic pain relievers. The CBHSQ 
Report. Retrieved from 
https://www.samhsa.gov/data/sites/default/files/report_2083/ShortReport-2083.pdf 
 
Dahlman, D., Håkansson, A., Björkman, P., Blomé, M. A., & Kral, A. H. (2015). Correlates of 
skin and soft tissue infections in injection drug users in a syringe-exchange program in 
Malmö, Sweden. Substance Use and Misuse, 50(12), 1529–1535. 
https://doi.org/10.3109/10826084.2015.1023450 
43 
 
 
Dahlman, D., Håkansson, A., Kral, A. H., Wenger, L., Ball, E. L., & Novak, S. P. (2017). 
Behavioral characteristics and injection practices associated with skin and soft tissue 
infections among people who inject drugs: A community-based observational study. 
Substance Abuse, 38(1), 105–112. https://doi.org/10.1080/08897077.2016.1263592 
 
Dahlman, D., Jalalvand, F., Blomé, M. A., Håkansson, A., Janson, H., Quick, S., & Nilsson, A. 
C. (2017). High Perineal and Overall Frequency of Staphylococcus aureus in People Who 
Inject Drugs, Compared to Non-Injectors. Current Microbiology, 74(2), 159–167. 
https://doi.org/10.1007/s00284-016-1165-y 
 
Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartelson, B., 
& Green, J. L. (2015). Trends in Opioid Analgesic Abuse and Mortality in the United 
States. New England Journal of Medicine, 372(3), 241–248. 
https://doi.org/10.1056/NEJMsa1406143 
 
Doherty, C. (2013). Americans see U.S. losing ground against mental illness, prescription drug 
abuse | Pew Research Center. Retrieved February 28, 2019, from 
http://www.pewresearch.org/fact-tank/2013/11/13/americans-see-u-s-losing-ground-against-
mental-illness-prescription-drug-abuse/ 
 
Dunleavy, K., Munro, A., Roy, K., Hutchinson, S., Palmateer, N., Knox, T., … Taylor, A. 
(2017). Association between harm reduction intervention uptake and skin and soft tissue 
infections among people who inject drugs. Drug and Alcohol Dependence, 174, 91–97. 
https://doi.org/10.1016/j.drugalcdep.2017.01.020 
 
Fernandes, R. M., Cary, M., Duarte, G., Jesus, G., Alarcão, J., Torre, C., … Carneiro, A. V. 
(2017). Effectiveness of needle and syringe Programmes in people who inject drugs - An 
overview of systematic reviews. BMC Public Health. https://doi.org/10.1186/s12889-017-
4210-2 
 
Goldstein, E. J. C., Wurcel, A. G., Merchant, E. A., Clark, R. P., & Stone, D. R. (2015). 
Emerging and Underrecognized Complications of Illicit Drug Use. Clinical Infectious 
Diseases, 61(12), 1840–1849. https://doi.org/10.1093/cid/civ689 
 
Grau, L. E., Arevalo, S., Catchpool, C., & Heimer, R. (2002). Expanding Harm Reduction 
Services Through a Wound and Abscess Clinic. American Journal of Public Health, 92(12), 
1915–1917. https://doi.org/10.2105/AJPH.92.12.1915 
 
Hagan, H., Pouget, E. R., & Des Jarlais, D. C. (2011). A Systematic Review and Meta-Analysis 
of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs. The 
Journal of Infectious Diseases, 204(1), 74–83. https://doi.org/10.1093/infdis/jir196 
 
Han, B., Compton, W. M., Blanco, C., Crane, E., Lee, J., & Jones, C. M. (2017). Prescription 
44 
 
opioid use, misuse, and use disorders in U.S. Adults: 2015 national survey on drug use and 
health. Annals of Internal Medicine, 167(5), 293–301. https://doi.org/10.7326/M17-0865 
 
Harris, M., Brathwaite, R., McGowan, C. R., Ciccarone, D., Gilchrist, G., McCusker, M., … 
Hope, V. (2018). “Care and Prevent”: Rationale for investigating skin and soft tissue 
infections and AA amyloidosis among people who inject drugs in London. Harm Reduction 
Journal. https://doi.org/10.1186/s12954-018-0233-y 
 
Hays, R. D., & Morales, L. S. (2001). The RAND-36 measure of health-related quality of life. 
Annals of Medicine, 33(5), 350–357. https://doi.org/10.3109/07853890109002089 
 
Hellard, M., Rolls, D. A., Sacks-Davis, R., Robins, G., Pattison, P., Higgs, P., … McBryde, E. 
(2014). The impact of injecting networks on hepatitis C transmission and treatment in 
people who inject drugs. Hepatology, 60(6), 1861–1870. https://doi.org/10.1002/hep.27403 
 
Hooton, C. (2015). Neuroscientist Carl Hart: People will always use drugs, we must learn to live 
with this fact | The Independent. Retrieved February 15, 2019, from 
https://www.independent.co.uk/news/world/americas/neuroscientist-carl-hart-people-will-
always-use-drugs-we-must-learn-to-live-with-this-fact-10435621.html 
 
Hope, V., Kimber, J., Vickerman, P., Hickman, M., & Ncube, F. (2008). Frequency, factors and 
costs associated with injection site infections: Findings from a national multi-site survey of 
injecting drug users in England. BMC Infectious Diseases, 8(1), 120. 
https://doi.org/10.1186/1471-2334-8-120 
 
Ivan, M., Beek, I. van, Wand, H., & Maher, L. (2015). Surveillance of injecting‐related injury 
and diseases in people who inject drugs attending a targeted primary health care facility in 
Sydney’s Kings Cross. Australian and New Zealand Journal of Public Health, 39(2), 182–
187. https://doi.org/10.1111/1753-6405.12363 
 
Ivan, M., Rodgers, C., Maher, L., & Van Beek, I. (2016). Reducing injecting-related injury and 
diseases in people who inject drugs: Results from a clinician-led brief intervention. 
Australian Family Physician, 45(3), 129–133. Retrieved from 
https://search.informit.com.au/documentSummary;dn=926714955476647;res=IELHEA 
 
Jette, A. M. (2018). Responding to the Opioid Epidemic in the United States. Physical Therapy, 
98(3), 147–148. https://doi.org/10.1093/ptj/pzx120 
 
Kiluk, B. D., Dreifuss, J. A., Weiss, R. D., Morgenstern, J., & Carroll, K. M. (2013). The Short 
Inventory of Problems - revised (SIP-R): psychometric properties within a large, diverse 
sample of substance use disorder treatment seekers. Psychology of Addictive Behaviors : 
Journal of the Society of Psychologists in Addictive Behaviors, 27(1), 307–314. 
https://doi.org/10.1037/a0028445 
 
45 
 
Lake, S., & Kennedy, M. C. (2016). Health outcomes associated with illicit prescription opioid 
injection: A systematic review. Journal of Addictive Diseases, 35(2), 73–91. 
https://doi.org/10.1080/10550887.2015.1127712 
 
Larney, S., Peacock, A., Mathers, B. M., Hickman, M., & Degenhardt, L. (2017). A systematic 
review of injecting-related injury and disease among people who inject drugs. Drug and 
Alcohol Dependence, 171, 39–49. https://doi.org/10.1016/j.drugalcdep.2016.11.029 
 
Laurent, R. T. St. (1998). Evaluating Agreement with a Gold Standard in Method Comparison 
Studies. Biometrics, 54(2), 537. https://doi.org/10.2307/3109761 
 
Levy, C. S. (2017). NASW Code of Ethics. Social Work, 30(5), 451–452. 
https://doi.org/10.1093/sw/30.5.451 
 
Lewer, D., Harris, M., & Hope, V. (2017). Opiate Injection-Associated Skin, Soft Tissue, and 
Vascular Infections, England, UK, 1997-2016. Emerging Infectious Diseases, 23(8), 1400–
1403. https://doi.org/10.3201/eid2308.170439 
 
Lim, S., Vos, T., Flaxman, A., Danaei, G., & Shibuya, K. (2012). A comparative risk assessment 
of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 
regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet, 380. 
 
Marlatt, G. A., Blume, A. W., & Parks, G. A. (2001). Integrating Harm Reduction Therapy and 
Traditional Substance Abuse Treatment. Journal of Psychoactive Drugs, 33(1), 13–21. 
https://doi.org/10.1080/02791072.2001.10400463 
 
Martin, N. K., Hickman, M., Hutchinson, S. J., Goldberg, D. J., & Vickerman, P. (2013). 
Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: 
Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate 
Substitution Therapy. Clinical Infectious Diseases, 57(suppl_2), S39–S45. 
https://doi.org/10.1093/cid/cit296 
 
McLellan, A. T., Alterman, A. I., Cacciola, J., Metzger, D., & O’Brien, C. P. (1992). A new 
measure of substance abuse treatment. Initial studies of the treatment services review. The 
Journal of Nervous and Mental Disease, 180(2), 101–110. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/1737971 
 
McNeil, R., & Small, W. (2014). ‘Safer environment interventions’: A qualitative synthesis of 
the experiences and perceptions of people who inject drugs. Social Science & Medicine, 
106, 151–158. https://doi.org/10.1016/J.SOCSCIMED.2014.01.051 
 
Metrebian, N., Groshkova, T., Hellier, J., Charles, V., Martin, A., Forzisi, L., … Strang, J. 
(2015). Drug use, health and social outcomes of hard-to-treat heroin addicts receiving 
46 
 
supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable 
Opioid Treatment Trial (RIOTT). Addiction, 110(3), 479–490. 
https://doi.org/10.1111/add.12748 
 
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & 
Degenhardt, L. (2011). Global epidemiology of hepatitis B and hepatitis C in people who 
inject drugs: results of systematic reviews. The Lancet, 378(9791), 571–583. 
https://doi.org/10.1016/S0140-6736(11)61097-0 
 
Patel, M., Foote, C., Duwve, J., Chapman, E., Combs, B., Fry, A., … Broz, D. (2018). Reduction 
of injection-related risk behaviors after emergency implementation of a syringe services 
program during an HIV outbreak. Journal of Acquired Immune Deficiency Syndromes, 
77(4), 373–382. https://doi.org/10.1097/QAI.0000000000001615 
 
Phillips, K. T., Anderson, B. J., Herman, D. S., Liebschutz, J. M., & Stein, M. D. (2017). Risk 
Factors Associated with Skin and Soft Tissue Infections among Hospitalized People Who 
Inject Drugs. Journal of Addiction Medicine, 11(6), 461–467. 
https://doi.org/10.1097/ADM.0000000000000346 
 
Phillips, K. T., Stein, M. D., Anderson, B. J., & Corsi, K. F. (2012). Skin and needle hygiene 
intervention for injection drug users: Results from a randomized, controlled Stage I pilot 
trial. Journal of Substance Abuse Treatment, 43(3), 313–321. 
https://doi.org/10.1016/j.jsat.2012.01.003 
 
Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., … Hickman, M. (2018). 
Needle and syringe programmes and opioid substitution therapy for preventing HCV 
transmission among people who inject drugs: findings from a Cochrane Review and meta-
analysis. Addiction, 113(3), 545–563. https://doi.org/10.1111/add.14012 
 
Ronan, M. V., & Herzig, S. J. (2016). Hospitalizations related to opioid abuse/dependence and 
associated serious infections increased sharply, 2002-12. Health Affairs, 35(5), 832–837. 
https://doi.org/10.1377/hlthaff.2015.1424 
 
Smith, M. E., Robinowitz, N., Chaulk, P., & Johnson, K. E. (2014). Self-care and risk reduction 
habits in older injection drug users with chronic wounds: A cross-sectional study. Harm 
Reduction Journal. https://doi.org/10.1186/1477-7517-11-28 
 
Spiller, M. W., Broz, D., Wejnert, C., Nerlander, L., Paz-Bailey, G., Centers for Disease Control 
and Prevention (CDC), & National HIV Behavioral Surveillance System Study Group. 
(2015). HIV infection and HIV-associated behaviors among persons who inject drugs--20 
cities, United States, 2012. MMWR. Morbidity and Mortality Weekly Report, 64(10), 270–
275. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25789742 
 
Stancliff, S., Phillips, B. W., Maghsoudi, N., & Joseph, H. (2015). Harm Reduction: Front Line 
47 
 
Public Health. Journal of Addictive Diseases, 34(2–3), 206–219. 
https://doi.org/10.1080/10550887.2015.1059651 
 
Tinker, B. (2019). These states have been hit the hardest by America’s opioid epidemic. CNN. 
Retrieved from https://www.cnn.com/2019/02/22/health/opioid-deaths-states-
study/index.html 
 
Tookes, H., Diaz, C., Li, H., Khalid, R., & Doblecki-Lewis, S. (2015). A Cost Analysis of 
Hospitalizations for Infections Related to Injection Drug Use at a County Safety-Net 
Hospital in Miami, Florida. PLOS ONE, 10(6), e0129360. 
https://doi.org/10.1371/journal.pone.0129360 
 
Wallace, B., Barber, K., & Pauly, B. (Bernie). (2018). Sheltering risks: Implementation of harm 
reduction in homeless shelters during an overdose emergency. International Journal of 
Drug Policy, 53, 83–89. https://doi.org/10.1016/j.drugpo.2017.12.011 
 
Werb, D. (2018). Post-war prevention: Emerging frameworks to prevent drug use after the War 
on Drugs. International Journal of Drug Policy, 51, 160–164. 
https://doi.org/10.1016/j.drugpo.2017.06.012 
 
Wiessing, L., Ferri, M., Běláčková, V., Carrieri, P., Friedman, S. R., Folch, C., … Liddell, D. 
(2017). Monitoring quality and coverage of harm reduction services for people who use 
drugs: A consensus study. Harm Reduction Journal, 14(1). https://doi.org/10.1186/s12954-
017-0141-6 
 
Wilson, D. P., Donald, B., Shattock, A. J., Wilson, D., & Fraser-Hurt, N. (2015). The cost-
effectiveness of harm reduction. International Journal of Drug Policy. 
https://doi.org/10.1016/j.drugpo.2014.11.007 
 
Wood, E., McKinnon, M., Strang, R., & Kendall, P. (2012). Improving community health and 
safety in Canada through evidence-based policies on illegal drugs. Open Med, 6. 
 
Wurcel, A. G., Anderson, J. E., Chui, K. K. H., Skinner, S., Knox, T. A., Snydman, D. R., & 
Stopka, T. J. (2016). Increasing Infectious Endocarditis Admissions Among Young People 
Who Inject Drugs. Open Forum Infectious Diseases, 3(3), ofw157. 
https://doi.org/10.1093/ofid/ofw157 
 
Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B., Iqbal, K., Ward, J. W., & Holtzman, D. 
(2018). Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid 
Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. American 
Journal of Public Health, 108(2), 175–181. https://doi.org/10.2105/AJPH.2017.304132 
 
 
48 
 
APPENDIX A 
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Table 7 
Demographics and Sanitation 
 Gender Level of 
Education 
Inject 
DOC 
Reuse Injection 
Equipment 
Hand 
Washing 
Antiseptic 
usage 
Soap usage Shared 
Needles 
Shared 
Equipment 
Overdosed 
Gender 1 -.072 .159 .242* -.186 -.151 -.040 .028 .147 -.044 
Level of 
Education 
-.072 1 -.025 -.045 .100 .174 .183 .001 -.278** .158 
Inject DOC .159 -.025 1 .319** -.260* -.320** -.251* .123 .173 -.130 
Reuse Injection 
Equipment 
.242* -.045 .319** 1 -.137 -.167 .009 .315** .408** -.152 
Hand Washing -.186 .100 -.260* -.137 1 .681** .677** -.236* -.358** .080 
Antiseptic usage -.151 .174 -.320** -.167 .681** 1 .657** -.282** -.379** .109 
Soap usage -.040 .183 -.251* .009 .677** .657** 1 -.204 -.244* .030 
Shared Needles .028 .001 .123 .315** -.236* -.282** -.204 1 .355** -.272* 
Shared Equipment .147 -.278** .173 .408** -.358** -.379** -.244* .355** 1 -.254* 
Overdosed -.044 .158 -.130 -.152 .080 .109 .030 -.272* -.254* 1 
(*)   Correlation is significant at the 0.05 level (2-tailed).            
(**) Correlation is significant at the 0.01 level (2-tailed).  
 
 
Table 8 
Injection Drug Use, Sanitation and Health Problems 
 Inject 
DOC 
Reuse Injection 
Equipment 
Antiseptic 
usage 
Soap usage New sterile water Shared Needles Hand 
Washing 
Chronic Medical 
Problems 
Inject DOC 1 .319** -.320** -.251* -.222* .123 -.260* .013 
Reuse Injection 
Equipment 
.319** 1 -.167 .009 -.123 .315 -.137 -.051 
Antiseptic usage -.320** -.167 1 .657** .498** -.282** .681** .073 
Soap usage -.251* .009 .657** 1 .567** -.204 .677** .160 
New sterile water -.222* -.123 .498** .567** 1 -.404** .544** .138 
Shared Needles .123 .315** -.282** -.204 -.404** 1 -.236* -.100 
Hand Washing -.260* -.137 .681** .677** .544** -.236* 1 -.085 
Chronic Medical 
Problems 
.013 -.051 .073 .160 .138 -.100 -.085 1 
(*)   Correlation is significant at the 0.05 level (2-tailed).            
(**) Correlation is significant at the 0.01 level (2-tailed).  
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Figure 1. Heroin Use - Past 30 Days 
 
Figure 2. Fentanyl Use - Past 30 Days 
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Figure 3. Other Opioid Use (Oxycodone / OxyContin) - Past 30 Days 
 
 
Figure 4. Preferred Drug of Choice 
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Figure 5. Do You Inject Your Drug of Choice 
 
 
Figure 6. When was the last time you injected a drug? 
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Figure 7. During the past month have you reused any of your injection equipment like 
Needles, Cookers, Cotton, or Tourniquets? 
 
Figure 8. Before you inject, do you wash your hands first? 
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Figure 9. Before you inject, do you clean the skin where you plan to inject with Alcohol, 
Iodine, or other Antiseptic? 
 
 
Figure 10. Before you inject, do you clean the skin where you plan to inject with soap 
and water? 
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Figure 11. Do you use new, sterile, unshared water each time you inject? 
 
 
Figure 12. What location do you use to inject your substances most often? 
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Figure 13. If you have a preference, what area of the body do you frequently use as your 
injection site? 
 
 
Figure 14. Have you shared needles in the last 30 days? 
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Figure 15. Have you shared other equipment besides needles (e.g., cookers, spoons, 
cotton, tourniquets/tie offs) in the last 30 days? 
 
 
Figure 16. How many times in your life have you overdosed from the misuse of opioids 
(e.g., heroin or Oxycontin)? 
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Figure 17. How many times in your life have you been hospitalized for medical problems 
(exclude detox, alcohol/drug treatment, and childbirth)? 
 
 
Figure 18. Do you have any chronic medical problems which continue to interfere with 
your life? 
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Figure 19. Do you have any chronic medical problems which continue to interfere with 
your life? 
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